SUMITOMO CHEMICAL COMPANY,LIMITED [4005.T]
TOKYO, Apr 08 (Pulse News Wire) – Sumitomo Chemical Company,limited (4005.T) announced plans to issue up to April 08, 2026 new shares, aiming to raise funds for strategic initiatives outlined in its “Boost 2028” growth strategy. Key priorities include accelerating the launch of two cancer drugs—enzomenib and nuvisertib—and enhancing research and development capabilities across various therapeutic areas.
The company expects the capital increase to strengthen its financial foundation and support long-term value creation. In addition to securing funding for near-term projects, Sumitomo Pharma intends to reallocate existing debt, reducing reliance on interest-bearing liabilities. The move aligns with the company's broader goal of improving financial health while maintaining robust operations and investment flexibility.
Sumitomo Pharma also highlighted its commitment to shareholder returns, emphasizing stable dividend payouts tied to performance improvements. The company reported no dividends paid in fiscal years 2023, 2024, and 2025 due to losses incurred during those periods. Moving forward, Sumitomo Pharma aims to balance sustainable growth with regular dividend distributions based on operational success.
🔴 Confidence: Review recommended AI-translated content.